STOCK TITAN

Geron Corp - GERN STOCK NEWS

Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.

Geron Corporation (GERN) is a clinical-stage biopharmaceutical company advancing novel oncology therapies through its telomerase inhibitor research. This page provides investors and industry professionals with verified updates on clinical developments, regulatory milestones, and strategic initiatives.

Access the latest press releases and analysis related to imetelstat's progress in treating hematologic malignancies like myelodysplastic syndromes. Our curated collection ensures you stay informed about trial results, partnership announcements, and scientific presentations without speculative commentary.

Key updates include details on Phase 3 clinical trials, FDA communications, intellectual property developments, and collaboration agreements. All content is sourced directly from official company channels to maintain accuracy and compliance.

Bookmark this page for streamlined access to Geron's evolving story in cancer therapeutics. Check back regularly for objective reporting on advancements in telomerase-targeted treatment approaches.

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) announced the granting of non-statutory stock options for 220,000 shares to new employees as employment inducements. These options were issued on April 21, 2021, with an exercise price of $1.48, matching the closing stock price on the grant date. The options have a 10-year term and vest over four years, with an initial 12.5% vesting at the six-month mark. This action complies with Nasdaq Listing Rule 5635(c)(4). Geron is currently focused on developing its telomerase inhibitor, imetelstat, through two Phase 3 clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
-
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) has initiated dosing for the first patient in its Phase 3 clinical trial, IMpactMF, studying imetelstat for refractory myelofibrosis (MF), with overall survival as the primary endpoint. This trial, targeting 320 patients, addresses a significant unmet need given the median overall survival of 14-16 months for those unresponsive to JAK inhibitors. Interim results are anticipated in 2024, with final results expected in 2025. Imetelstat is also Fast Track designated by the FDA for certain patient populations, enhancing its development prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) announced the issuance of non-statutory stock options for 240,000 shares to newly hired employees. These options were granted on March 17, 2021, at an exercise price of $1.81 per share, matching the stock's closing price on that date. The options have a 10-year term and vest over four years, with 12.5% vesting after six months of employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan aimed at attracting new talent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) reported its financial results for Q4 and FY 2020, ending with $260 million in cash and marketable securities, expected to last until late 2022. The company is advancing its Phase 3 trials for imetelstat in hematologic malignancies, with IMerge Phase 3 expected to be fully enrolled in H2 2021. However, COVID-19 has caused delays in enrollment. Fiscal 2020 net loss was $75.6 million, with revenues of $253,000. Geron anticipates operating expenses between $108 and $112 million in 2021 while preparing for a potential NDA submission in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.99%
Tags
-
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) will announce its fourth quarter and full year 2020 financial results on March 11, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and recent developments. Interested participants can access the call via a pre-registration link. Geron focuses on developing imetelstat, a telomerase inhibitor, currently being tested in two Phase 3 trials: IMerge for lower-risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis. More details are available on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
-
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options totaling 431,600 shares to newly hired employees as part of their employment incentives. The options, issued on February 17, 2021, have an exercise price of $1.99 per share, aligning with Geron's closing stock price on the grant date. The vesting period is set over four years, beginning with 12.5% at six months, followed by equal installments thereafter. This grant adheres to Nasdaq rules and is part of Geron's 2018 Inducement Award Plan.

Geron focuses on developing imetelstat, a telomerase inhibitor, in hematologic malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.74%
Tags
none
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options for 120,000 shares of common stock to newly hired employees as an employment inducement. The options were granted on January 20, 2021, with an exercise price of $1.74 per share, matching the closing stock price on the grant date. These options have a 10-year term and vest over four years. This action complies with Nasdaq Listing Rule 5635(c)(4) and aligns with Geron's 2018 Inducement Award Plan. Geron is focused on developing imetelstat, a telomerase inhibitor, in hematologic cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
none
-
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) announced that CEO John A. Scarlett will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on January 20 at 3:00 p.m. ET. The presentation will be accessible via a live audio webcast on Geron's website, with a replay available for 30 days post-event.

Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor targeting hematologic myeloid malignancies. For further details, visit www.geron.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
-
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) has announced the launch of the IMpactMF Phase 3 clinical trial for imetelstat, a telomerase inhibitor targeting refractory myelofibrosis (MF). This trial aims to enroll approximately 320 patients and assess the drug's ability to extend overall survival and improve symptoms, following promising Phase 2 results. The primary endpoint will focus on overall survival, with secondary endpoints covering various clinical outcomes. The trial incorporates over 150 sites globally, though potential COVID-19-related delays are acknowledged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) has achieved fifty percent enrollment in the IMerge Phase 3 clinical trial for imetelstat, targeting lower risk myelodysplastic syndromes (MDS). This milestone is crucial for advancing the trial, which aims to assess transfusion independence and disease-modifying effects of imetelstat. The trial is set to enroll approximately 170 patients, with top-line results expected in the second half of 2022, provided enrollment completes by mid-2021.

Imetelstat is the first telomerase inhibitor in development, offering a potential treatment alternative for MDS patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
Geron Corp

Nasdaq:GERN

GERN Rankings

GERN Stock Data

808.88M
632.77M
0.1%
78.42%
9.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY